製品、イベント、会社情報などのインデナの文書を閲覧できます。
セクションに移動
科学を通して見る
スクロールして詳細を見る
ベルベヴィス®に関する査読付き論文
ONCE A DAY FOR METABOLIC BALANCE1
Berbevis® has already proven its effectiveness in modulating body composition and balancing the lipid profile. A recent study further validates that all its positive effects can be achieved with a single daily 550-mg dose. Specifically, the study administered Berbevis® to two different populations: subjects with stable hyperlipidemia (n=47; SM + Berbevis® vs SM + placebo) and with occasional hyperlipidemia (n=25; SM + Berbevis® vs baseline). In both cases, Berbevis® showed a positive influence on body composition and lipid profile (see Figures 1 and 2).
Figure 1: Effects of a single daily dose of Berbevis® in stably hyperlipidemic subjects, considering HDL, total cholesterol, TG and body composition (weight and fat/muscle ratio).
Figure 2: Effects of a single daily dose of Berbevis® in occasionally hyperlipidemic subjects, considering HDL, total cholesterol, TG and body composition (weight and fat/muscle ratio).
より良い代謝1に貢献する。
Berbevis® has a positive effect on body composition, inducing a redistribution of adipose tissue even if enrolled subjects aren't under low calorie diet (Figure 3,4)2.
Figure 3. Descriptive statistics for the body composition measured at baseline (t0) and after 60 days (t2) of Berbevis® supplementation.W/H: Waist/Hip Ratio; BMI: Body Mass Index. *p<0.05; **p <0.005.
Figure 4. Effectiveness on body composition, inducing a redistribution of adipose tissue with the reduction of the visceral fat tissue and fat mass. *p<0.005.
血糖値を下げる2。
Berbevis® positively modulates insulin resistance (HOMA index) after 30 days of supplementation (Figure 5). The homeostatic model assessment (HOMA) is a mathematical formula correlating blood glucose and insulin. It's a validated method used to quantify insulin resistance and function of pancreatic beta-cells (which produce insulin). The higher is the HOMA score, the higher is the risk of insulin resistance.
Figure 5. Effect of Berbevis® on HOMA index in PCOS individuals (*p≤0.005).
Berbevis® significantly improves blood sugar profile optimizing both glucose and insulin (Figure 6)2.
Figure 6. Effect of Berbevis® on the glycemic profile in PCOS individuals (*p≤0.005; **p<0.0005).
ベルベリス・フィトソーム®はベルベリンの生体吸収を最適化します3。
A pharmacokinetic study has shown Berbevis® improves berberine's bioavailability (AUC) by ≈ 10 times on molar basis and with observed dose linearity. The pharmacokinetic profile of total and free berberine after the administration of Berbevis® and of berberine chloride to healthy volunteers is shown in Figure 7.
Figure 7. Statistical analysis performed by two-way ANOVA, followed by Tukey's test, *p<0.05 vs A, § p<0.05 vs B. Symbols represent mean values (± standard deviation). The formulations used were A: berberine chloride alone 500 mg (equivalent to 452 mg of berberine); B: Berbevis® 550 mg (equivalent to 188 mg of berberine) in one film-coated tablet; C: Berbevis® 550 mg (equivalent to 188 mg of berberine) in two film-coated tablets. Twelve healthy volunteers of both sexes with a mean age of 29 ± 7.72 and a mean BMI of 23.09 ± 1.27 were enrolled in the study.
BIBLIOGRAPHY
1Cesarone MR, et al. Minerva Gastroenterol (2024).
2Rondanelli M , et al. Nutrients 13 (2021).
3Riva et al. Indena data on file.
